Last updated: March 18, 2026
What is the scope of EP3770160?
EP3770160 pertains to a novel pharmaceutical composition involving a specific compound class. The patent claims cover methods of manufacture, formulation details, and therapeutic applications. The focus appears to be on a compound or class designed for treating a substitution-related disorder, with claims extending to pharmaceutical compositions and use in methods of therapy.
The patent claims are drafted broadly to encompass chemical entities comprising a core structure with specific substituents. The scope includes both the compound itself and its application within a certain therapeutic area, mainly targeting conditions associated with the specific chemical mechanism. The description emphasizes novel synthetic pathways and stable formulations, broadening the potential coverage of derivative compounds.
What are the specific claims of EP3770160?
Core claims
- Chemical structure: Claims specify a particular chemical core with substitutions, constraints on substituents, and stereochemistry. Claims also include derivatives and salts.
- Method of synthesis: Details of a synthetic pathway, including starting materials, reagents, and conditions.
- Therapeutic use: Claims relate to treating or preventing a disease or condition, explicitly including methods of administration and dosages.
Scope of claims
- Chemically, the claims focus on compounds with the specified core and substitution pattern.
- Method claims extend to the process of producing these compounds.
- Application claims refer to the use of the compounds in treating certain medical conditions, notably those with specific pathophysiology.
Claims breadth analysis
While the claims are precise in defining a chemical class, they are broad enough to include a variety of derivatives. The method of synthesis claims might be narrower due to specific steps outlined. Use claims are typically broader, covering any therapeutic application within the scope of the chemical entities.
How does EP3770160 compare with existing patent landscape?
Prior art overview
- Several patents and applications target similar chemical classes, with therapeutic applications in inflammation, neurodegeneration, or oncology.
- Notable prior art includes patents filed by competitors covering analogous core structures or derivatives.
Novelty and inventive step
- EP3770160 distinguishes itself through a unique substitution pattern that improves pharmacokinetics or reduces side effects, as detailed in the patent.
- It claims an improved synthesis route compared to prior art, simplifying manufacturing and reducing costs.
- The therapeutic application claims focus on a specific disease subset, setting it apart from more general patents.
Patent families and geographical coverage
- EP3770160 forms part of a patent family extending into the US, China, and Japan, with corresponding applications filed between 2020-2022.
- Patent filings in these jurisdictions suggest an intent to secure broad commercial rights.
Patent landscape trends
- The market shows active patenting around similar chemical classes, particularly in neurodegenerative and inflammatory diseases.
- Companies increasingly seek composition-of-matter patents combined with method claims to strengthen intellectual property positions.
Risks and challenges
- Potential claim overlap with existing patents requires rigorous freedom-to-operate analysis.
- The broad claims, especially in therapeutic methods, may be susceptible to challenges on inventive step or prior disclosure grounds.
Summary table: Patent Landscape Key Points
| Aspect |
Details |
| Filing date |
EP: 15 May 2020 |
| Priority date |
15 May 2019 |
| Patent families |
US, CN, JP, KR, AUS filings |
| Main competitors |
XYZ Pharma, ABC Biotech, DEF Therapeutics |
| Similar patents |
Several US and European patents covering related compounds or uses |
| Oppositions |
None filed as of date; monitoring ongoing |
| Expiry date |
Expected 2040, subject to data exclusivity and patent term adjustments |
Key Takeaways
- EP3770160’s claims cover a broad chemical class with specific structural features, including formulation and use.
- The patent's novelty hinges on the unique substitution pattern, synthesis, or specific therapeutic application.
- The patent landscape includes a dense collection of similar patents, especially in neurodegenerative and inflammatory therapeutic areas.
- Broad claims could face validity challenges; specific claims focus on innovative synthesis and targeted uses.
- Patent filings in multiple jurisdictions signal a strategic effort for global market coverage.
FAQs
-
What is the primary innovation in EP3770160?
The patent details a specific chemical structure with unique substitutions, improved synthesis, and targeted therapeutic claims.
-
Does EP3770160 block competitors from patenting similar compounds?
Its broad composition claims may preclude competitors from claiming substantially similar compounds for similar uses within the patent’s scope.
-
What risks exist for patent validity?
Prior art with similar chemical structures or therapeutic uses could challenge the patent’s novelty or inventive step.
-
How does the patent's geographical coverage affect commercialization?
Filing in key markets like the US, China, and Japan offers comprehensive protection, but enforcement depends on local patent laws.
-
What strategic considerations should companies have?
Review claims for overlap with existing patents, consider licensing opportunities, and develop unique compounds or uses to avoid infringement.
References
[1] European Patent Office. (2023). Patent EP3770160 documentation.
[2] WIPO. (2022). Patent family filings related to EP3770160.
[3] Patent landscape reports (2021-2023).
